A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Trial Profile

A Phase 1b Study of SAR650984 (Anti-CD38 mAb) in Combination With Lenalidomide and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 31 May 2018

At a glance

  • Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Isatuximab (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Acronyms LenCombo
  • Sponsors Sanofi
  • Most Recent Events

    • 25 May 2018 Planned End Date changed from 4 Jan 2019 to 28 Dec 2018.
    • 25 May 2018 Planned primary completion date changed from 4 Jan 2019 to 28 Dec 2018.
    • 11 Apr 2018 Planned End Date changed from 15 May 2019 to 4 Jan 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top